LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on…
- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with…
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence…
Blue Cross' Center for Prevention will support six organizations and one Tribal nation to reduce commercial tobacco use in disproportionately…
With $3.5 million in funding from the GI Research Foundation, a team at the MD Anderson Cancer Center explores a…
Following the successful TREK-AD Phase 2b study of eblasakimab in moderate-to-severe atopic dermatitis, process is underway to identify potential partners.…
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence"…
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence"…
Accomplished pharmaceutical and biotechnology executive to lead IMUNON’s clinical programs in ovarian cancer and infectious diseases LAWRENCEVILLE, N.J., Dec. 11,…
KELOWNA, BC / ACCESSWIRE / December 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology…